Ecthymatous skin eruption during therapy with cetuximab

European Journal of Dermatology

Volumn 21, Issue 2, 2011, Pages 282-283

  Navarini, Alexander A ^a   Kamacharova, Ilina ^a   Kerl, Katrin ^a   Donghi, Davide ^a   Cozzio, Antonio ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CETUXIMAB; CIPROFLOXACIN; FLUOROURACIL; HYALURONIC ACID; IODINE; STEROID; SULFADIAZINE; TRICLOSAN;

ACNE; ADULT; ADVANCED CANCER; CASE REPORT; CELL INFILTRATION; CONJUNCTIVITIS; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRY SKIN; ECTHYMATOUS SKIN ERUPTION; ENTEROBACTER CLOACAE; EOSINOPHIL; FEMALE; HAIR LOSS; HISTIOCYTE; HUMAN; LETTER; LUNG METASTASIS; LYMPHOCYTE; MESOPHARYNX CANCER; MULTIPLE CYCLE TREATMENT; PARONYCHIA; PHARYNX CANCER; SKIN BIOPSY; STAPHYLOCOCCUS AUREUS; STOMATITIS; ULCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN ULCER;

EID: 79960761875     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1281     Document Type: Letter

References (6)

1. Steiner JG, Trüeb RM, Mühleisen B, French LE, Hofbauer GFH. Ecthyma gangrenosum-like bullous pemphigoid. Dermatology 2010; 221: 142-8.
2. Fernandez-Torres R, Martinez Gomez W, Cuevas Santos J, Paradela S, Fonseca Capdevila E. Rosaceiform eruption induced by cetuximab. Eur J Dermatol 2010; 20: 392-3.
3. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4: 107-19.
4. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3: 599-606.
5. EMEA, Agency. EM: Erbitux (cetuximab) drug information: http://wwwemeaeuropaeu/humandocs/PDFs/EPAR/erbitux/H-558-PI-enpdf, 2009, 2009.
6. de Noronha e Menezes NM, Lima R, Moreira A, et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: A prospective and descriptive study of 19 patients. Eur J Dermatol 2009; 19(3): 248-51.